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Abstract
With the aging of the population, Parkinson’s disease poses a serious  
socio-economic problem; there is no effective therapy that can arrest/revert the 
progression of the disease. The hallmarks of Parkinson’s disease and other synucle-
inopathies are the disordered alpha-synuclein and TPPP/p25. These proteins have 
neomorphic moonlighting characteristics by displaying both physiological and 
pathological functions. Physiologically TPPP/p25 regulates the dynamics/stability 
of the microtubules and is crucial for oligodendrocyte differentiation; while alpha-
synuclein is involved in neuronal plasticity modulation and synaptic vesicle pool 
maintenance. In healthy brain, alpha-synuclein and TPPP/p25 occur predominantly 
in neurons and oligodendrocytes, respectively; however, they are co-enriched and 
co-localized in both cell types in brain inclusions in the cases of Parkinson’s disease 
and multiple system atrophy, respectively. The pathomechanisms of these diseases 
are largely unknown; the fatal species are the small, soluble homo- and hetero- 
associations of alpha-synuclein. These proteins with their high conformational plas-
ticity and chameleon feature are challenging drug targets. Nevertheless, the contact 
surface of TPPP/p25-alpha-synuclein assemblies has been validated as a specific drug 
target. This new strategy with innovative impact, namely targeting the interface of 
the TPPP/p25-alpha-synuclein complex, could contribute to the development of  
anti-Parkinson drugs with unique specificity.
Keywords: alpha-synuclein, TPPP/p25, pathological assemblies, drug target, 
innovative therapy
1. Introduction
With the aging of society, neurological disorders have become more and more 
widespread resulting in serious social and economic problems. Parkinson’s disease 
(PD) is the second most common neurodegenerative disease [1]. The etiology of 
this disease is initiated by unfolded/misfolded proteins, which form homologous 
and/or heterologous oligomers leading to the formation of aggregates and inclu-
sions such as Lewy bodies predominantly comprised of alpha-synuclein (SYN) as 
histopathological hallmarks [1, 2].
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At the present time, there is no proven therapy that can counteract the progres-
sion of the disease. The symptomatic therapies may reverse or slow down the 
progression of the symptoms, but cannot arrest/revert the neurodegenerative pro-
cess [3]. The motor impairments of PD are attributed to the loss of dopaminergic 
neurons in the substantia nigra pars compacta; the phenotype is characterized by 
rigidity, resting tremor and bradykinesia [1]. The gold standard drug in the clinical 
practice is the L-dopa (or levodopa), precursor of dopamine, which relieves these 
motor symptoms by the replacement of the lost dopamine; however, large variabil-
ity in drug response in terms of efficacy and adverse reactions have been observed 
[3, 4]. These side effects of conventional anti-parkinsonian drugs have compelled 
the researchers to seek novel alternatives such as gene therapy, stem cells transplants 
and neuroprotective agents [3]. The latest progression for the therapy suggests 
further opportunities (applications of antibodies, antisense-oligonucleotides and 
small molecules) that decrease the SYN level and its aggregation in the brain, some 
of them are now under clinical trials [3, 5].
One of the important factors in the PD research is related to the finding that 
SYN displays both physiological and pathological functions [5]; consequently, 
besides the specific and effective destruction of the accumulated SYN leading to 
the formation of its toxic assemblies/aggregations, the optimal SYN level has to be 
maintained/ensured for its physiological functions. In this chapter, the structural 
and functional potentials of SYN and Tubulin Polymerization Promoting Protein 
(TPPP/p25), hallmarks of PD [6], are reviewed leading to their molecular mecha-
nism/pathomechanism in the initiation of PD and other synucleinopathies.
2. SYN and its physiological associations
SYN is an unstructured protein, prototype of the chameleon proteins [7]. 
Although the intrinsically disordered SYN is predominantly unfolded under physi-
ological conditions, helically folded tetrameric structure or the combination of the 
two also have been suggested as its native structure [8]. In response to environmen-
tal changes, the disordered SYN is able to adopt significant conformational changes 
with different amount of secondary structures determined by pH, temperature, 
presence of organic solvents, membranes or specific metal ions [7, 9]. The structure 
of SYN have been studied in details under a plethora of distinct circumstances 
[10–12]. Structurally SYN comprises three regions: the N-terminal region involved 
in lipid binding; the highly hydrophobic central NAC region; and the acidic 
unfolded C-terminus, which exhibits chaperone activity and may counteract the 
aggregative potency of SYN [5, 13, 14] (Figure 1). The disordered C-terminal 
segment of SYN (45 aa) was found to modulate its aggregation, however, a terminal 
peptide (30 aa) was ineffective as a competitor in the aggregation process, which is 
characteristic for chameleon proteins [7].
The central hydrophobic region of SYN corresponding to residues 71–82 was 
found to be essential for its misfolding and aggregation, while a second critical 
region (residues 45–57) is of great importance in mediating β-strand to β-strand 
interactions in the fibril conformation [8]. Mutations are localized (18–53 aa) within 
the N-terminal region of SYN involved in lipid-binding. Based on comparative 
analysis of SYN structure, the 32–58 aa region was assigned as a crucial one to ensure 
the stability and secondary structure of SYN [15]. This issue is in agreement with 
another study which revealed the prominent role of a similar segment (39–45 aa) of 
the protein in membrane penetration [16]. SYN mutants with increased oligomer-
ization efficacy are more inclined to penetrate the membrane [17].
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In normal brain, SYN binds to the surface of synaptic vesicles [5, 18]. 
Although it is highly disordered when isolated in solution; however, its micelle-
bound form displays a partial helical structure that could be formed into curved 
α-helices [14, 19] (Figure 1). In spite of the data accumulated so far, the physio-
logical function of SYN is still unclear in details. Membrane bound conformations 
of SYN are likely mediate its physiological function including the modulation of 
neuronal plasticity, synaptic vesicle pool maintenance, and dopamine metabolism 
[5, 13]. Moreover, it has been proposed that it can function as a microtubule regu-
latory protein (dynamase) [20–22]; as a disordered hub protein it also interacts 
with at least 50 ligands and other proteins [23].
The role of molecular chaperones in the regulation of the physiological function 
of SYN has been recently reviewed [24]. These interactions reduce the amount of 
free SYN in the cells and thus prevent its structural transition towards pathological 
states. Heat shock proteins (Hsp) are molecular chaperones that assist in proper 
conformational binding of proteins; they display protective effect against their tox-
icity and counteracts aggregation [25, 26]. SYN interacts with Hsp90 and Hsp70 as 
shown by co-immunoprecipitation [27]. The modulation of the proteolytic degrada-
tion of SYN by inhibiting Hsp90 function or by promoting Hsp70 function resulted 
in enhanced degradation of the aggregated protein. In fact, this issue has been 
suggested for treatment of PD against SYN toxicity [25]. Small molecules, which 
either directly interact with SYN or modulate molecular chaperones, were found to 
decrease SYN aggregation in vitro or in some animal models of PD; however, there 
is no clinical proof for their efficacy yet [25].
3. SYN mutations and pathological assemblies
SYN was the first identified causative gene of familial PD, all identified muta-
tions can be found in the N-terminal region that affect the oligomerization, fibril-
lation and/or aggregation of SYN leading to the formation of the toxic species, 
see [1, 5, 6] and references therein. Until now, the following mutants have been 
Figure 1. 
Schematic representation of SYN. Familial mutations related to PD (green), and phosphorylation sites 
(red) are indicated. 3D structure of the human micelle-bound alpha-synuclein determined by NMR (DOI: 
10.2210/pdb1XQ8/pdb) [14].
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identified to be involved in PD: A18T, A29S, A30P, E46K, H50Q, G51D, A53E and 
A53T [28] (Figure 1). There are mutants (A18T, A29S, E46K, H50Q and A53T) that 
increase SYN aggregation, others (G51D and A53E) slow down its aggregation; 
while the A30P mutation increases the oligomerization, yet hinders the fibrillation 
[29, 30]. G51D mutation, although the slowest to aggregate, is the most potent of 
the known early onset mutations supporting the hypothesis that increased lifetime 
of smaller oligomers can impart toxic effects [8]. The post-translational modifica-
tions, such as Ser129, Ser87 and Tyr125 phosphorylation, could also display various 
effects on the SYN assembly. The phosphorylation of SYN on Ser129 is negligible 
in normal brain, but it is the dominant form in Lewy bodies [31]. However, the 
effects of these modifications on the drug/ligand binding of SYN have not been 
clarified yet.
Two cellular pathways are involved in SYN clearance trying to maintain its 
physiological protein level: the ubiquitin-proteasome system (UPS) [32] and the 
autophagy-lysosomal pathway [33–35]. UPS is involved in proteolytic degradation 
of short-lived, damaged and misfolded protein; while the degradation of the long-
lived and aggregated protein as well as that of the damaged organelles are achieved 
by macroautophagy (autophagy) and the selective chaperone-mediated autophagy 
(CMA) [36–38]. Macroautophagy degrades cellular waste through the fusion of the 
autophagosomes, carrying the material, with the lysosomes containing hydrolyses. 
Whereas CMA degrades soluble cytosolic proteins containing a specific CMA motif 
related to the pentapeptide KFERQ. The cytosolic chaperone heat-shock cognate 
70 kDa protein (Hsc70) recognizes this motif, then it delivers the targeted protein to 
the lysosomes, and after binding to the lysosomal-associated membrane protein 2A 
(LAMP-2A), the targeted protein is translocated into the lysosomal lumen.
Genetic and post-mortem studies have suggested that modifications occur 
in both macroautophagy and CMA in the case of PD [39]. Mutations or post-
translational modifications of SYN can also affect its turnover by CMA, such as the 
A30P and A53T mutants, related to familial cases of PD, which are not efficiently 
degraded through CMA, they can bind LAMP-2A, but are not internalized inside 
the lysosomes [40]. The protein level of the LAMP-2A, a key CMA marker, can be 
decreased in the substantia nigra of PD brains as compared to controls [41], while 
its protein level correlates with increased SYN accumulation in the affected PD 
brain regions.
The inhibition of the chaperone-SYN interaction facilitates the binding of SYN 
forming amphipathic helix into the lipid bilayer of the mitochondria membrane 
leading to membrane disruption [24]. SYN interaction with mitochondria occurs 
at higher protein expression or impaired chaperone-SYN ratio; therefore, the 
pathological conditions result in the failing of its CMA-derived proteolytic degrada-
tions [24]. Therapeutic strategies aiming to increase the SYN degradation through 
activation of these clearance pathways have thus been deeply explored in order to 
re-establish physiological levels of the protein and prevent its accumulation in PD 
[25, 42, 43]. The most interactions of SYN with mitochondria occur in cells in the 
case of oxidative stress [44] that can promote SYN aggregation associated with 
mitochondrial dysfunction [45, 46]. The localization of the enriched SYN on the 
mitochondrial membrane can produce destructive effect. Cellular oxidative stress is 
known to be a common factor driving synucleinopathy progression [44, 47].
Under oxidative stress conditions DJ-1, a cellular protease, is translocated from 
the cytoplasm to the mitochondria [48, 49]. DJ-1 is able to interact with both mono-
meric and oligomeric SYN counteracting its oligomerization propensity [50]. The 
crucial role of DJ-1 to control the aggregated SYN in proximity of mitochondria is 
also reflected by the fact that DJ-1 has been found in the proximity of Lewy bodies 
[51, 52]. Mutations within DJ-1 associated with PD reduce the capacity of DJ-1 to 
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prevent toxic SYN assemblies [53–55]. The ability of DJ-1 to inhibit SYN aggrega-
tion appears to be dependent on the oxidation of its Cys106 residue (Cys106-SO2
− 
form) [50, 56, 57]. SYN overexpression activates CMA by elevating the levels of 
LAMP-2A; however, DJ-1 deficiency suppressed this effect. Experiments with DJ-1 
knockout (KO) mice and DJ-1 siRNA knockdown SH-SY5Y cells confirmed that 
DJ-1 deficiency increased the accumulation and aggregation of SYN in both models, 
by accelerating the degradation of LAMP-2A, a lysosome-associated membrane 
protein. DJ-1 deficiency also downregulated the level of lysosomal Hsc70 [52]. 
These findings provide evidence for the molecular interaction between PD-related 
proteins via the CMA pathway.
In recent years, emerging evidence points out that microglial and astrocytic 
dysfunction may also play an important role in the pathogenesis of PD [40]. Several 
genes associated with PD are also expressed in glial cells, displaying comparable 
or even higher levels than in neurons, which are also involved in inflammatory 
response, oxidative stress, lysosomal and mitochondrial function, and autophagy. 
Perturbations in DJ-1 may alter different glial processes that can impact neuronal 
survival, DJ-1-deficient microglia displayed elevated intracellular reactive oxygen 
species and nitric oxide leading to increased dopaminergic neurotoxicity [58]. 
Recently it has been suggested that primary cortical astrocytes form DJ-1 KO mice 
may provide decreased neuroprotection to surrounding neurons due to alterations 
in pro-inflammatory mediator expression [52].
The cytoskeletal microtubule system plays a crucial role in several physiological 
and pathological processes which is achieved by the decoration of this filamen-
tous network with proteins/enzymes as well as post-translational modifications 
[59]. The microtubule associated proteins/enzymes regulate these intracellular 
processes such as cell division, differentiation, autophagy, intracellular traffick-
ing and aggresome formation by modulating microtubule dynamics and stability. 
Destabilization of the microtubule network, low tubulin acetylation levels and axo-
nal transport deficits have been observed in PD [60, 61]. SYN has been described as 
a microtubule dynamase [21] and it also interacts with microtubule stabilizing pro-
teins such as tau and TPPP/p25 [22, 59]. SYN binds within the microtubule-binding 
domain of tau and may promote its hyperphosphorylation resulting in impaired 
axonal transport [62]. The microtubule associated tau and TPPP/p25 stabilize the 
microtubule network [22, 59].
4. TPPP/p25, a multifunctional microtubule associated protein
Physiologically, TPPP/p25 modulates the dynamics and stability of the microtu-
bule network by bundling the microtubules and enhancing the tubulin acetylation 
due to the inhibition of tubulin deacetylases [59, 63]. In normal brain, TPPP/p25 
is expressed in oligodendrocytes (OLGs) and a key factor in the growth of projec-
tions in the course of differentiation requested for the axon ensheathment [64]. 
Therefore, the optimal endogenous TPPP/p25 level plays key physiological functions 
in the formation of differentiated OLGs, which are key players in myelin sheath 
formation.
TPPP/p25 is an intrinsically disordered protein without a well-defined 3D struc-
ture, whose middle, highly flexible CORE region is straddled by the unstructured 
N- and C-termini [65] (Figure 2). Two human gene sequences have been identi-
fied, which encode homologous proteins displaying approximately 60% identity 
with TPPP/p25. These proteins are N-terminal-free forms denoted as TPPP/p18 
and TPPP/p20 [66]. The similarity of TPPP/p25 to TPPP/p20 is manifested in their 
intrinsically disordered characteristics and association to microtubules [66]. 3D 
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structure of TPPP/p20, but not TPPP/p25, has been determined by NMR (from 
TPPP/p20 the unfolded N-terminal tail of TPPP/p25 is missing) [67]. TPPP/p20 
is involved in developmental processes of the musculoskeletal system [68], and 
surprisingly, not in neurodegenerative, rather in cancerous processes due to its 
modulation of the cell proliferation, see [59] and references therein.
TPPP/p25 occurs in monomeric and dimeric forms, the dimeric form displays 
enhanced tubulin polymerization promoting activity [69]. The UPS is the major 
system responsible for the elimination of the disordered TPPP/p25 suggested by the  
finding that MG132, a well-established inhibitor of proteasome, enhanced the 
intracellular TPPP/p25 level [70, 71]. The stabilization of TPPP/p25 against the pro-
teolytic degradation is resulted from the structural changes of the protein coupled 
with its dimerization which is essential for the maintenance of the stability of the 
myelin sheath.
The forms of plasticity of synapsis within the OLG lineage as well as the con-
nection of the OLG and myelin dysfunction in neurodevelopmental disorders with 
cognitive symptoms have recently been described [72]. The OLG precursor cells 
proliferate and some of them differentiate. A subset of these new OLGs integrates 
into sheaths on unmyelinated axon segments. In this process, TPPP/p25 could be a 
key player since its endogenous expression is involved in the differentiation of the 
dividing progenitor cells under post-transcriptional control [64]. In the course of 
this process, the plasticity of the myelin sheath might be modified.
Recently in has been shown that TPPP/p25 KO mice have shorter lamellar 
microtubules, and consequently shorter and thinner myelin sheaths [73]. Cultured 
TPPP/p25 KO OLGs also displayed additional aberrant features, including more 
proximal branches, mixed microtubule polarity and accumulation of myelin 
basic protein mRNA. In the brain of these mice, decreased myelination have been 
observed, although no gross differences were found in neurofilament staining, 
indicating that axonal tracts and neuronal morphology is largely intact [73]. 
Concerning the behavior of TPPP/25 KO mice, their anxiety behavior has been 
similar as in the case of wild type mice, however, they lack fear responses. Deficits 
in fear-conditioning, which is a memory dependent task, as well as in spatial 
memory tests support possible short-term memory defects [74]. Experiments with 
TPPP/p25 KO mice that exhibit hypomyelination with aberrant myelin sheaths and 
motor coordination deficits have suggested that microtubule nucleation outside the 
Figure 2. 
Schematic representation of TPPP/p25. Phosphorylation sites (red) are indicated. 3D structure of the 
homologous TPPP/p20 determined by NMR (DOI: 10.2210/pdb2JRF/pdb) [67].
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cell body at Golgi outposts by TPPP/p25 is critical for the elongation of the myelin 
sheath [73]. In fact, elevation of the TPPP/p25 level was detected in rat brain in the 
course of aging [75], however, it is unclear whether it is due to increased demand 
or aberrant accumulation. The latter issue may be related to the development of 
different neurological disorders such as Alzheimer’s disease (AD), PD, multiple 
system atrophy (MSA) and diffuse Lewy body disease (DLBD); however, increased 
TPPP/p25 level was detected with remyelinating lesions in the case of multiple 
sclerosis [76].
5. From TPPP/p25-SYN interaction to their co-localization in Lewy body
TPPP/p25, as a moonlighting protein, performs distinct functions under physi-
ological and pathological conditions without alterations at gene level [77]. This 
feature of TPPP/p25 manifested primarily itself in its association with SYN, the 
hallmark of PD. Pathologically, TPPP/p25 interacts with SYN resulting in its oligo-
merization/aggregation [78]. Studies with various truncated and deletion mutants 
of the human TPPP/p25 produced by recombinant techniques revealed significantly 
reduced, but not abolished interaction with SYN [79, 80]. These findings indicated 
that the lack of identified binding segments of the wild type TPPP/p25 could be 
replaced by other segments [81]. Although it has been well-established that SYN is 
also a disordered protein; notwithstanding, the neomorphic chameleon characteristic 
was introduced for TPPP/p25 to indicate the distinction of the two disordered 
proteins. Namely, the modifications of TPPP/p25 at gene level is able to maintain its 
associative potency [81]; in contrast to this, the deletion of the last 20 amino acid 
residues of SYN abolished its interaction with TPPP/p25 [80].
The unfolded SYN and TPPP/p25 are expressed distinctly in neurons [82, 83] 
and OLGs [64, 75], respectively, in healthy brain; however, they are co-enriched 
and co-localized in pathological inclusions in the cases of PD and MSA [84]. The 
interaction of SYN and TPPP/p25 has been proven at atomic, molecular and cellular 
levels as well as in post-mortem brain tissues [6, 59]. Short peptide fragments have 
been produced by proteolytic degradation of the interacting proteins as well as by 
chemical synthesis based upon the interface segments identified experimentally 
using the wild type proteins [79, 80]. The interactive and aggregative potencies 
of the wild type and truncated forms of SYN and/or TPPP/p25 were visualized 
by immunofluorescence microscopy (Figure 3). Massive co-aggregation of the 
two hallmark proteins were achieved by the contact surface-containing fragments 
instead of the full proteins.
The interaction of TPPP/p25 with SYN has been extensively characterized at 
atomic, molecular, cellular and tissue levels using wild type and mutant human 
recombinant proteins and living human cell models [6, 59, 85]. The interaction 
of SYN and TPPP/p25 in living cells was visualized by immunofluorescent confo-
cal microscopy coupled with Bifunctional Fluorescent Complementation (BiFC) 
technology using mVenus vectors [81]. The immunofluorescence images presented 
in Figure 4 verify the hetero-association of TPPP/p25 and SYN at cellular level; the 
hetero-association (green fluorescence) is reduced due to the addition of unlabeled 
TPPP/p25 as a competitor, which provides evidence for the dynamic and specific 
association of the two disordered proteins [81].
The hetero-association induced by the excess SYN and TPPP/p25 results in the 
appearance of massive aggregates [79–81]. The co-enrichment and co-localization 
of TPPP/p25 and SYN specific for synucleinopathies were established in post-
mortem human brain tissues of patients with PD and other neurological disorders 
(Figure 5). TPPP/p25 is enriched in filamentous SYN bearing Lewy bodies of PD 
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and DLBD, as well as in glial inclusions of MSA [84]. In contrast to synucleinopa-
thies, no co-localization was found between TPPP/p25 and phosphorylated tau in 
inclusions of Pick’s disease (PiD), progressive supranuclear palsy (PSP), and corti-
cobasal degeneration (CBD). It is worth noting that clustered immunoreactivity of 
TPPP/p25 was found along filaments of unstructured but not compact neurofibril-
lary tangles in the case of AD. Based on these findings TPPP/p25 was suggested to 
be a novel marker of alpha-synucleinopathies [84].
Co-immunoprecipitation analysis carried out on HEK293T and oligodendroglial 
KG1C cell lines with ectopically expressed SYN and TPPP/p25 corroborated the 
specific interaction of the two proteins; moreover, TPPP/p25 is able to induce SYN 
oligomerization [86, 87]. Recently an oligodendroglial cell model of MSA has been 
studied, in which after the overexpression of TPPP/p25 and uptake of human 
Figure 3. 
Intracellular co-enrichment and co-localization of wild type SYN and TPPP/p25 as well as their fragments in 
CHO10 cells [80]. Uptake of SYN and/or TPPP/p25 by CHO10 cells from the medium following their premixing 
as detected by immunofluorescence microscopy. Nuclei were counterstained with 4,6-diamidino-2-phenylindole 
(blue). Scale bar: 5 μm.
Figure 4. 
Dynamic association of TPPP/p25 with SYN in living HeLa cells as visualized by BiFC technology [81].  
(A) Scheme of BiFC constructs for co-transfection of TPPP/p25 and SYN. (B): Visualization of the association 
of mVN-SYN and VC-TPPP/p25 (green). Effect of the unlabeled TPPP/p25 on the association of TPPP/p25 
with SYN (BiFC) signal. Bar: 10 μm. (C) Quantification of the relative BiFC signal.
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pre-formed SYN fibrils, the cells formed insoluble, highly aggregated, pathologi-
cal assemblies [86]. Mavroeidi and his co-workers have also revealed that these 
assemblies resulted in the disruption of the microtubule and myelin networks 
[86] indicating the toxic potential of the pathological TPPP/p25-SYN assembly. In 
addition, the formation of the glial cytoplasmic inclusion was suggested due to the 
endogenously expressed hallmark proteins. In the case of MSA, early relocation 
of TPPP/p25 (from the myelin sheath and the nucleus to the cytoplasm) has been 
observed [88, 89].
In normal brain SYN and TPPP/p25 are expressed predominantly in neurons 
and in OLGs, respectively [64, 75, 82, 83]. However, these two hallmark proteins 
are co-enriched and co-localized in Lewy bodies and glial cytoplasmic inclusions 
characteristic for PD and MSA, respectively [84, 87, 90]. The intra- and extracel-
lular transmission of SYN forms between neurons as well as between neurons and 
OLGs in the case of PD and MSA has been established [91, 92]. In addition, the 
presence of both proteins in the extracellular space has been reported inasmuch as 
their occurrence in the cerebrospinal fluid (CSF) [93–95], their cellular uptake from 
the medium were also detected [79, 96]. Consequently, the cell-to-cell transmission 
as a pathological situation can be mimicked in cells models such as HeLa by taking 
up SYN and/or TPPP/p25 from the medium [79–81].
The mechanism of this process is unclear yet, however, the liberation of the 
endocytosed materials in the cytoplasm by the mechanism of “endosomal escape” 
to reach autophagic vacuole has been proposed [97]. This mechanism could take 
place in the case with the exogenously applied SYN and/or TPPP/p25. Endocytosis 
has a special relevance in the brain, because of its involvement in neurotransmitter 
and neurotrophic signaling. Since neuronal cells are highly polarized, they require 
a highly specialized and complex endocytic machinery. Alterations in this complex 
system have also been described in PD [40]. Besides conventional endocytosis, 
exosomal transport, receptor-mediated internalization, passive diffusion, or even 
direct penetration of the plasma membrane have been suggested as possible path-
ways for SYN uptake [98].
6. Innovative strategy for PD and MSA therapy
In a recent review Devos and co-workers have reported that “Despite decades 
of successful preclinical neuroprotective studies, no drug has then shown efficacy 
Figure 5. 
SYN and TPPP/p25 in post-mortem brain samples in the cases of PD (a), MSA (b), DLBD and AD (c) and 
AD (d), respectively [84].
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in clinical trials.” [99]. According to this and other publications, effective neu-
roprotective therapy is still an unmet need both in PD and MSA. Symptomatic 
treatments are available, although MSA patients usually show poor l-Dopa respon-
siveness [100]. Concerning possible disease-modifying therapies, the following 
strategies are under clinical trials: targeting SYN pathology such as active and pas-
sive immunization, anti-aggregative small molecules, RNA interference techniques 
and an increase in SYN clearance, intervening neuroinflammation or neuronal loss 
(by stem cells) [25, 92, 100–102]. Remyelinating molecules are also being tested in 
clinical trials in the case of MSA, since this disease is accompanied by myelin loss 
as well [100].
A recently reported innovative strategy is based upon the effective and specific 
inhibition/destruction of the pathological TPPP/p25-SYN complex/assembly by 
peptide fragments of the partner proteins [81]. The highly flexible foldamers that 
can recognize oligomers and proteins are among potential therapeutics. These 
foldamers are endowed with variable pharmacokinetic properties; nonetheless, 
their constructions with suitable recognition surfaces are still challenging; they 
have to display contiguous recognition surface or long sequences with broadly 
distributed recognition contacts, see [103] and references therein. Foldamer-based 
protein mimetics have been designed by following the principles of multivalent 
biomolecule-recognizing ligands [103, 104]. In fact, the fragment-based foldamer 
approach displays unnatural protein mimetics that are capable of specific molecular 
recognition and inhibition of multifunctional target.
The recognition that the TPPP/p25-derived SYN aggregation is involved in the 
pathomechanism of the synucleionopathies, but not in that of the tauopathies, 
underlined that the TPPP/p25-SYN complex is a potential drug target [79–81]. 
However, the complex as a whole could not be considered as an optimal drug target 
since both proteins display physiological functions as well, but the interface of their 
complex occurring only under pathological conditions was proposed to be an excel-
lent target. Thus, the interface of the complex of the two hallmark proteins has 
been validated at molecular and cellular levels [79–81]. The binding segments of 
TPPP/p25 involved in its interaction with SYN was identified (147–156 aa) [79–81] 
(Figure 6). The interface has been considered as a potential drug target, which is 
found to be distinct from the physiological TPPP/p25-tubulin one (178–187 aa). 
These findings showed the role of the middle, CORE region of TPPP/p25 in the 
formation of the pathological TPPP/p25-SYN complex; in addition, the stable 
complex was created by the interaction between the two unstructured proteins 
with sufficient avidity. Thus, short peptide fragments by targeting the interface 
of the pathological complex could function as potential anti-Parkinson agents. 
Figure 6. 
Distinct segments of TPPP/p25 involved in the physiological (tubulin) and pathological (SYN) interactions. 
Identified interface segments of the pathological TPPP/p25-SYN complex [6, 79].
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The effectiveness of these fragments can be tested by in vitro competition experi-
ments by ELISA using human recombinant proteins and by BiFC approach coupled 
by fluorescence microscopy [79–81]. The inhibition of the direct association of 
SYN with TPPP/p25 can be visualized and the inhibitory effect of the fragments 
can be quantified by the reduction of the fluorescence signal (green). This two-
steps-assay seems to be applicable to screen potential drug-like molecules for their 
anti-Parkinson activity. The innovative interface-targeting methodology allows one 
to further develop it to disease-related/unrelated interface targeting.
The recognition of the endogenous expression of SYN and TPPP/p25 in neurons 
and OLGs, respectively, offers opportunity for the selective influence of PD and MSA 
such as disease-dependent interface targeting of the pathological TPPP/p25-SYN 
complex. Let us consider the specific interface-targeting fragments that can inhibit 
and/or destruct the TPPP/p25-SYN assemblies. The nature of the interface fragments 
for elimination of the pathological complex has to be determined by their origin 
(TPPP/p25 or SYN fragments).
As illustrated in the scheme (Figure 7), in the case of PD the inclusions are 
formed predominantly in neurons, SYN, and not TPPP/p25, is expressed endog-
enously in these cells; in this situation a TPPP/p25 fragment can be effective to 
destruct the pathological complex in neurons without displaying side effects. 
Conversely, for the treatment of MSA, when the inclusions are formed in OLGs 
that express endogenously TPPP/p25, it is expected that SYN-based fragments 
could be effective to diminish the co-assemblies of SYN and TPPP/p25 in OLGs 
and no unwanted side effect occurs. These issues are based upon the recognition 
that TPPP/p25 is enriched in Lewy bodies of neurons exclusively in the case of 
PD, while SYN accumulates in OLGs in cytoplasmic inclusions according to the 
etiology of MSA.
PD, DLBD and MSA have some common features such as inclusion bodies 
comprised of SYN and TPPP/p25 as well as decline in motor, cognitive, behav-
ioral and autonomic functions. However, these diseases may be distinguished 
based on affected cell types and brain structures, the relative onset and prognosis 
[105, 106]. Cognitive impairment precedes parkinsonism in the case of DLBD, 
while PD dementia starts 1 year or more after the diagnosis of PD; DLBD patients 
show more profound cognitive impairments. Approximately ~30% of MSA 
patients also suffers from cognitive impairment, in particular executive dysfunc-
tion. The hippocampus is one of the most vulnerable brain regions affected 
Figure 7. 
Disease-dependent interface targeting of the pathological TPPP/p25-SYN complex. Targeting the interface by 
SYN or TPPP/p25 fragments for MSA and PD therapies.
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by synucleinopathies, and its dysfunction may result in cognitive deficits and 
depression. Oligomerization/aggregation of SYN was found to induce deficits 
in synaptic transmission and hippocampal neurogenesis, which may contribute 
to the appearance of cognitive deficits. Short-term memory defects have also 
been observed in TPPP/p25 KO mice, which exhibit hypomyelination [73, 74]. 
Recently it has been proposed that OLGs and myelin sheaths play crucial roles in 
memory and learning [72].
Clinically, the differentiation between PD and MSA is challenging, especially 
at the early stages of diseases [107]. In contrast to PD, no causal SYN mutations for 
MSA have been found to date. However, neuropathological hallmarks of both MSA 
and PD could be observed in the case of the G51D SYN mutant [108]. Two pos-
sible scenarios have been proposed to explain the origin of SYN in OLGs and SYN 
accumulation in glial cytoplasmic inclusions characteristic for MSA brains: either 
OLGs overexpress SYN under pathological conditions or they take up the neuronal 
protein from their environment, such as CSF [98]. The latter one, the cell-to-cell 
transmission has been proven. Recent studies have suggested that the SYN struc-
tures/aggregates formed in the cases of different synucleinopathies are distinct that 
could contribute to the discrimination between PD and MSA [107]. Nevertheless, 
it is important to notice that the aggregated structures amplified from CSF were 
similar to those ones amplified from the brain [107]. Biomarkers in CSF, such as 
phosphorylated/total tau, SYN and β-amyloid1–42, can be useful to distinguish PD 
or MSA patients from healthy controls, and SYN and total-tau could also be used to 
distinguish between MSA from PD [109]. The analysis of the hallmark TPPP/p25 
occurring in the CSF and inclusions of patients might provide more unambiguous 
information about the nature of synucleinopathies.
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